Document is current

Article History

Received: 22 April 2022

Accepted: 28 October 2022

First Online: 8 November 2022

Declarations

:

: The JME study was registered under UMIN 000008177. This study was approved by the National Hospital Organization Central Ethical Review Board. Using the informed consent form based on this approval, all patients were given opportunities and time to ask questions and decide whether or not to participate in the study. After confirming that the patient has fully understood the contents of the study, the patients were provided written consent for voluntary participation in this study. All methods in this study were performed in accordance with the relevant guidelines and regulations.

: Not applicable.

: HA, Honoraria: AstraZeneca, Boehringer Ingelheim Japan Inc, Bristol Myers Squibb, Eli Lilly Japan, Novartis Pharma, Ono Pharmaceutical, Taiho Pharmaceutical. Research Funding: Chugai Pharmaceutical, MSD. YK, Honoraria: Scrum, Nippon Boehringer Ingelheim, Eli Lilly, AstraZeneca, Eisai, Bristol-Myers Squibb, Takeda Pharmaceuticals. Consulting or Advisory Role: Tosoh. Research Funding: Nippon Boehringer Ingelheim, Daiichi Sankyo, Novartis, Chugai Pharmaceutical. MA, Honoraria: Eli Lilly, Taiho Pharmaceutical. Research funding: Kyowa Hakko Kirin. AK, Honoraria: Chugai Pharmaceutical. TK, Honoraria: Chugai Pharmaceutical. Research Funding: Chugai Pharmaceutical, Eli Lilly. NY, Honoraria: Bristol Myers Squibb, Thermo Fisher Scientific, Life Technologies Japan, Nippon Kayaku, Merck Biopharma. Research Funding: AstraZeneca, Astellas, Shionogi, Tsumura, AbbVie GK, Amgen, Kyorin, Eisai, Terumo, Toppan printing, Tosoh, Eli Lilly Ono Pharmaceutical, Daiichi Sankyo, Taiho, Takeda, Chugai, MSD, Novartis, Pfizer, Boehringer. Ingelheim. All the other authors declare no conflicts of interest.